Details for Patent: 9,662,342

Which drugs does patent 9,662,342 protect, and when does it expire?

Patent 9,662,342 protects CYCLOPHOSPHAMIDE and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 9,662,342

Title:	Formulations of cyclophosphamide liquid concentrate
Abstract:	Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C.
Inventor(s):	Nagesh R. Palepu, Philip Christopher Buxton
Assignee:	Eugia Us LLC
Application Number:	US14/702,320
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,662,342
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 9,662,342

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eugia Pharma Speclts	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	210735-002	Aug 25, 2021		RX	Yes	Yes			Y
Eugia Pharma Speclts	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	210735-003	Nov 20, 2023		RX	Yes	Yes			Y
Eugia Pharma Speclts	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	210735-001	Aug 25, 2021		RX	Yes	Yes			Y

International Family Members for US Patent 9,662,342

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015256331
Brazil	112016026140
Canada	2948148
China	106456654